Navigation Links
BioMS Medical's pivotal international multiple sclerosis trial receives positive review from Data Safety Monitoring Board
Date:4/21/2009

Toronto Stock Exchange Symbol: MS

EDMONTON, April 21 /PRNewswire-FirstCall/ - BioMS Medical Corp. (TSX: MS), a leading developer in the treatment of multiple sclerosis (MS), today announced that the independent Data Safety Monitoring Board (DSMB) for the Company's pivotal phase III MAESTRO-01 Canadian/European trial of dirucotide in patients with secondary progressive MS has completed a safety analysis and recommended that the trial continue as per the protocol.

This was the final scheduled review by the DSMB prior to the completion of MAESTRO-01. The purpose of the DSMB is to provide objective, independent safety monitoring of the trial. Results from MAESTRO-01 are expected in the second half of this year.

    About MAESTRO-01
    ----------------

MAESTRO-01 is a multi-center, double-blind, placebo-controlled trial designed to evaluate the safety and efficacy of dirucotide in patients with secondary progressive MS. The study is being conducted at 47 sites across Canada and nine countries in Europe and includes 611 patients being administered either dirucotide or placebo intravenously every six months for a period of two years. The primary clinical endpoint for the trial is defined as a statistically and clinically significant increase in the time to progression of the disease, as measured by the Expanded Disability Status Scale (EDSS), in patients with HLA-DR2 and/or HLA-DR4 immune response genes (up to 70% of all MS patients are HLA-DR2 and/or HLA-DR4 positive). Time to disease progression in patients with other HLA-DR types will be assessed separately as an exploratory arm of the same study.

    About BioMS Medical Corp.
    -------------------------

BioMS Medical is a biotechnology company engaged in the development and commercialization of novel therapeutic technologies. BioMS Medical's lead technology, dirucotide, is for the treatment of multiple sclerosis and is being evaluated in two pivotal phase III clinical trials for Secondary Progressive MS patients, MAESTRO-01 in Canada and Europe and MAESTRO-03 in the United States. In December 2007, BioMS entered into a licensing and development agreement granting Eli Lilly and Company exclusive worldwide rights to dirucotide in exchange for an $87 million upfront payment, milestone payments and escalating royalties on sales. For further information please visit our website at http://www.biomsmedical.com

This press release may contain forward-looking statements, which reflect the Company's current expectation regarding future events. These forward-looking statements involve risks and uncertainties that may cause actual results, events or developments to be materially different from any future results, events or developments expressed or implied by such forward-looking statements. Such factors include, but are not limited to, changing market conditions, the successful and timely completion of clinical studies, the establishment of corporate alliances, the impact of competitive products and pricing, new product development, uncertainties related to the regulatory approval process and other risks detailed from time to time in the Company's ongoing quarterly and annual reporting. Certain of the assumptions made in preparing forward-looking statements include but are not limited to the following: that MBP8298 will continue to demonstrate a satisfactory safety profile in ongoing and future clinical trials; and that BioMS Medical Corp. will complete the respective clinical trials within the timelines communicated in this release. We undertake no obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events or otherwise.


'/>"/>
SOURCE BioMS Medical Corp.
Copyright©2009 PR Newswire.
All rights reserved

Related biology technology :

1. BioMS Medicals phase III U.S. multiple sclerosis trial receives positive safety review from Data Safety Monitoring Board
2. BioMS Medical Announces 2008 Year End Results
3. BioMS Medical warrant extension
4. BioMS Medical to present at BIO CEO and Investor Conference
5. BioMS Medical reports results of exploratory phase II trial of dirucotide in relapsing remitting multiple sclerosis
6. BioMS Medical recognized at Scrip Awards 2008
7. BioMS Medical Announces Third Quarter 2008 Results
8. BioMS Medical to present at Rodman and Renshaw Annual Healthcare Conference
9. BioMS Medicals relapsing-remitting multiple sclerosis trial receives positive review from Data Safety Monitoring Board
10. BioMS Medicals phase III U.S. multiple sclerosis trial receives positive safety review from Data Safety Monitoring Board
11. BioMS Medical announces receipt of milestone payment from Eli Lilly and Company
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/25/2017)... 25, 2017 Providence ... its novel immune-modulating technology to an undisclosed global pharmaceutical ... Tregitopes, pronounced T·rej·itopes, are a set ... EpiVax CEO Annie De Groot and ... G, an autoimmune disease therapy, Tregitopes are capable ...
(Date:4/25/2017)... (PRWEB) , ... April 25, 2017 , ... ... Services and Metrology Partners.     , Covalent’s Analytical Services unit provides high-quality ... can be measured within 24 hours of receipt. There are no price premiums, ...
(Date:4/24/2017)... Linda, Ca (PRWEB) , ... April 24, 2017 ... ... protect proteins from thermal denaturation in a cellular milieu; however, the broad application ... a lack of simple platforms with sensitive quantitative readouts. Cell-based thermal stabilization assays ...
(Date:4/21/2017)... ... April 21, 2017 , ... The 2017 Colorado Manufacturing ... over 30 nominees and well as the first-year award for 2017 Manufacturing Women ... event was hosted by CompanyWeek and Manufacturers Edge, among other sponsors. , ...
Breaking Biology Technology:
(Date:3/23/2017)... Research and Markets has announced the addition ... - Industry Forecast to 2025" report to their offering. ... The Global Vehicle ... around 8.8% over the next decade to reach approximately $14.21 billion ... estimates and forecasts for all the given segments on global as ...
(Date:3/22/2017)... , March 21, 2017 Vigilant Solutions ... serving law enforcement agencies, announced today the appointment of ... director of public safety business development. Mr. ... enforcement experience, including a focus on the aviation transportation ... most recent position, Mr. Sheridan served as the Aviation ...
(Date:3/16/2017)... CeBIT 2017 - Against identity fraud with DERMALOG solutions "Made in Germany ... ... one project, multi-biometric solutions provide a crucial contribution against identity fraud. (PRNewsFoto/Dermalog Identification Systems) ... Used combined in one project, multi-biometric solutions provide a crucial contribution ... ...
Breaking Biology News(10 mins):